GleamWall
中文EN

REGN REGENERON PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 872589 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY5.2%
TTM EPS YoY8.4%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR6.5%

Margins

Gross margin—
Operating margin28.8%
Net margin28.5%
FCF margin22.6%
EBITDA margin31.8%

Returns

ROE14.9%
ROA11.4%
ROIC (approx.)13.2%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.06x
Current ratio3.35x
Interest coverage104.16x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio-0.1%
Payout ratio8.0%
Capex / revenue6.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$14.34B$14.20B
R&D expense$5.85B$5.13B
SG&A expense$2.70B$2.95B
Operating income$3.58B$3.99B
Interest expense$43.80M$55.20M
Pretax income$5.23B$4.78B
Income tax$725.80M$367.30M
Net income$4.50B$4.41B
EBITDA$4.12B$4.47B
EPS (basic)43.0740.90
EPS (diluted)41.4838.34
Weighted avg. shares (diluted)108.60M115.10M
Balance sheet
Cash & equivalents$3.12B$2.49B
Short-term investments$5.49B$6.52B
Receivables$5.74B$6.21B
Inventory$3.20B$3.09B
Current assets$18.02B$18.66B
PP&E, net$5.12B$4.60B
Intangibles$1.26B$1.15B
Total assets$40.56B$37.76B
Current liabilities$4.37B$3.94B
Long-term debt$1.99B$1.98B
Total debt$1.99B$1.98B
Total liabilities$9.30B$8.41B
Shareholders' equity$31.26B$29.35B
Net debt-$1.13B-$504.60M
Cash flow statement
Operating cash flow$4.98B$4.42B
Capital expenditure$898.40M$755.90M
Free cash flow$4.08B$3.66B
Investing cash flow-$629.10M-$2.47B
Financing cash flow-$3.72B-$2.20B
Depreciation & amortization$543.70M$482.90M
Stock-based compensation$993.70M$982.80M
Dividends paid$370.30M$0
Share buybacks$3.44B$2.60B

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.